Department: Department of Biotechnology & Pharmacology
University: George Washington University
Country: United States
Dr. David Gortler had completed his basic science pharmacology research fellowship and post doctoral research in vascular and cardiovascular medicine at Yale University. He did his PharmD from University of Arizona, Tucson, AZ. He is currently serving as a professor at George Washington University for the departments of biotechnology, pharmacology and medicine. He is a research scientist and Former FDA Medical Officer/Senior Analyst who has served as a healthcare /FDA policy advisor on the 2016 Ted Cruz presidential campaign, and who has also been invited to testify in front of the U.S.Senate as a healthcare policy expert, FDA expert and Pharmacology expert. He served over a decade of didactic professorships at top-tiered medical schools (Yale, Georgetown, and George Washington Universities). He authored many publications in the areas of clinical and non-clinical pharmacology, ACA (“Obamacare”) replacement strategy, regulatory affairs, FDA law, FDA policy, drug pricing, drug safety, healthcare policy, drug development,epidemiology and drug patent law. Dr. David Gortler was one of the original 19 members that helped initiate Pfizer's research development program in HDL modulation and obesity.
His research interests mainly focuses on atherosclerosis, atheroprogression, vascular inflammation, /cholesterol metabolism, modulation, rhabdomyolysis, and obesity, drug development process he drug approval process, clinical trial design, evaluating drug safety.
Veterinary and Animal Medicine
Boffin Access Limited is committed to maintaining the integrity of the scholarly record to researchers. Therefore violation of professional ethical codes may lead to retract articles. Article(s) may be retracted if it is found to have serious flaws, reported misconduct research, constitute copyright infringement and plagiarism.
To help avoid the incorrect or misleading publications, please drop your message to
Enter your e-mail address to stay informed about published articles, issue releases and latest updates on journal activities.
We openly welcome feedback and constructive criticism. Your compliments, concerns and suggestions regarding our services will prove enormously helpful in making them even better.
Do you have an idea or suggestion that can influence the Open Access community? Send an email to: email@example.com
Copyright © 2020 Boffin Access Limited.